HOME > COMMENTARY
COMMENTARY
-
Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
-
Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
-
New Pricing System to Make e-Detailing More Important
February 1, 2010
-
Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
November 30, 2009
-
Verify Acceptability of Prices before Revising Pricing Rule
November 30, 2009
-
Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (2)
November 2, 2009
-
Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (1)
November 2, 2009
-
How Not to License a Drug into Japan
October 12, 2009
-
TOPICS/Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
-
NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
-
COMMENTARY/Pharma Industry Watches New DPJ Administration with Both Anticipation and Concerns
September 21, 2009
-
COMMENTARY/Will It Be Possible to Eliminate Use of Multiple Antipsychotics in Massive Doses?
September 14, 2009
-
COMMENTARY/Establish Solid Criteria for Switching Ethical Drugs to OTC Status
September 14, 2009
-
COMMENTARY/Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
-
COMMENTARY/Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
-
COMMENTARY/Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
-
COMMENTARY/Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
-
COMMENTARY/Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…